Resource Summary Report

Generated by dkNET on Sep 4, 2026

LNCaP clone FGC

RRID:CVCL_1379
Type: Cell Line

Proper Citation

RRID:CVCL_1379

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1379

Proper Citation: RRID:CVCL_1379

Description: Cell line LNCaP clone FGC is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Prostate carcinoma

Defining Citation: PMID:2734981, PMID:8104329, PMID:10092147, PMID:11172901, PMID:12725112, PMID:15389782, PMID:15833837, PMID:20164919, PMID:20215515, PMID:22460905, PMID:23117885, PMID:23325432, PMID:27397505, PMID:28145883, PMID:30305041, PMID:30894373, PMID:30971826, PMID:31068700, PMID:31395879, PMID:31978347, PMID:35839778

Comments: Population: Caucasian., Part of: TCGA-110-CL cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: LNCaP clone FGC

Synonyms: LNCaP-Clone-FGC, LNCaP.FGC, LNCaP-FGC, LNCaP FGC, LNCAPCLONEFGC, LNCaP-ATCC, LNCaP Fast Growing Colony

Cross References: BTO:BTO_0006095, CLO:CLO_0007366, CLO:CLO_0007367, CLO:CLO_0051537, EFO:EFO_0005726, CLDB:cl3245, CLDB:cl4960, CLDB:cl5222, 4DN:4DNSR4OQOB67, Abcam:ab275470, AddexBio:C0019003/4953, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-1740,

BCRC:60088, BCRJ:0149, BioGRID_ORCS_Cell_line:930, BioSample:SAMN03471417, BioSample:SAMN03472018, BioSample:SAMN05292444, BioSample:SAMN10988285, cancercelllines:CVCL_1379, CCRID:3101HUMSCSP5021, CCRID:3101HUMTCHu173, Cell_Model_Passport:SIDM00683, ChEMBL-Cells:CHEMBL3308342, ChEMBL-Targets:CHEMBL2366172, CLS:305220, Cosmic:688117, Cosmic:907788, Cosmic-CLP:907788, DepMap:ACH-000977, ECACC:89110211, EGA:EGAS00001000978, ENCODE:ENCBS089RMT, ENCODE:ENCBS184PDN, ENCODE:ENCBS235TSM, ENCODE:ENCBS260TRO, ENCODE:ENCBS386ENC, ENCODE:ENCBS387ENC, ENCODE:ENCBS418ENC, ENCODE:ENCBS421PUJ, ENCODE:ENCBS422ENC, ENCODE:ENCBS535BWO, ENCODE:ENCBS668DEO, ENCODE:ENCBS680JNS, ENCODE:ENCBS687TQL, ENCODE:ENCBS849SWQ, ENCODE:ENCBS851ZZS, ENCODE:ENCBS918PKZ, GDSC:907788, GEO:GSM383954, GEO:GSM383955, GEO:GSM383956, GEO:GSM651578, GEO:GSM651579, GEO:GSM827569, GEO:GSM887271, GEO:GSM888346, GEO:GSM1633299, GEO:GSM1633300, GEO:GSM1633301, GEO:GSM1633323, GEO:GSM1633324, GEO:GSM1633325, GEO:GSM1670051, GEO:GSM3407130, GEO:GSM3407131, GEO:GSM3407132, GEO:GSM3407133, GEO:GSM3407134, GEO:GSM3407135, IARC_TP53:27698, ICLC:HTL99011, IZSLER:BS TCL 148, KCB:KCB 200732YJ, KCLB:21740, LiGeA:CCLE_749, PharmacoDB:LNCaPCloneFGC_851_2019, PRIDE:PXD030304, Progenetix:CVCL_1379, PubChem_Cell_line:CVCL_1379, RCB:RCB2144, TKG:TKG 0603, Ubigene:YC-C009, Wikidata:Q54902825

ID: CVCL_1379

Hierarchy: cvcl_0395

Record Creation Time: 20220427T220731+0000

Record Last Update: 20260904T014546+0000

Ratings and Alerts

No rating or validation information has been found for LNCaP clone FGC.

No alerts have been found for LNCaP clone FGC.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 165 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Macke AJ, et al. (2026) Dynamic Shifts in ER-Plasma Membrane Junctions Signaling Define Pro-Metastatic N-Glycosylation and Predict Prostate Cancer Progression. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(30), e22885.

Wang J, et al. (2026) Systematic annotation of orphan RNAs reveals blood-accessible molecular barcodes of cancer identity and cancer-emergent oncogenic drivers. Cell reports. Medicine, 7(2), 102577.

Berzoti-Coelho MG, et al. (2026) PVT1 lincRNA signals an androgen-dependent transcriptional activation program of oncogenes in prostate cancer cells. International journal of cancer, 159(1), 144.

Rouhimoghadam M, et al. (2026) Mechanistic dissection of SMARCA2/4 molecular glues reveals programmable switching between DCAF16 and FBXO22. Cell chemical biology.

Kong X, et al. (2026) Anticancer Activity of Novel Trifluoromethylquinoline Derivatives Designed to Target the Tubulin Colchicine Binding Site. Chemistry & biodiversity, 23(6), e71420.

Zhang C, et al. (2026) GNL3 Orchestrates AR Transcriptional Programs to Drive Castration-Resistant Prostate Cancer and Immune Evasion. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(26), e16411.

Rodrigues SD, et al. (2026) Suppression of de novo lipogenesis and dietary PUFA supplementation inhibit prostate cancer progression. bioRxiv : the preprint server for biology.

Lobb RJ, et al. (2026) Early-stage multi-cancer detection through a plasma extracellular vesicle protein signature. Cell reports. Medicine, 7(4), 102694.

Tamarindo GH, et al. (2025) DHA suppresses hormone-sensitive and castration-resistant prostate cancer growth by decreasing de novo lipogenesis. Biochimica et biophysica acta. Molecular and cell biology of lipids, 1870(5), 159634.

Severson TM, et al. (2025) Epigenetic profiling identifies markers of endocrine resistance and therapeutic options for metastatic castration-resistant prostate cancer. Cell reports. Medicine, 6(7), 102215.

Khan S, et al. (2025) Synergistic Efficacy of Gedatolisib and Darolutamide in Prostate Cancer to Overcome Resistance to Androgen-Targeted Therapy. International journal of molecular sciences, 26(24).

Sipola J, et al. (2025) Plasma Cell-Free DNA Chromatin Immunoprecipitation Profiling Depicts Phenotypic and Clinical Heterogeneity in Advanced Prostate Cancer. Cancer research, 85(4), 791.

Chen Y, et al. (2025) ALKBH5-IGF2BP2 axis mediates prostate cancer progression and docetaxel resistance via m6A-stabilized CLSPN RNA. iScience, 28(10), 113520.

Thisted T, et al. (2025) Conditionally Active CD28xVISTA Bispecific Antibodies Promote Myeloid-Driven T-cell Activation. Cancer immunology research, 13(12), 1956.

ChallaSivaKanaka S, et al. (2025) DGAT1 as a Racially Divergent Driver of Carcinoma-Associated Fibroblast Activation Drives Tumorigenic Pathways via ERK1/2 Signaling in Prostate Cancer. bioRxiv : the preprint server for biology.

Cipolla R, et al. (2025) PROCA11 early activation fuels prostate cancer neuroendocrine traits by regulating cell survival and migration. iScience, 28(12), 113931.

Thomsen MT, et al. (2025) The olfactory receptor OR51E2 regulates prostate cancer aggressiveness and modulates STAT3 in prostate cancer cells and in xenograft tumors. BMC cancer, 25(1), 535.

Zhu S, et al. (2025) Isoform-specific function of NSD3 in DNA replication stress confers resistance to PARP inhibitors in prostate cancer. Molecular cell, 85(14), 2673.

Xiang RR, et al. (2025) CRISPR screening identifies regulators of enhancer-mediated androgen receptor transcription in advanced prostate cancer. Cell reports, 44(2), 115312.

Kudo KI, et al. (2025) Androgen receptor contributes to radioresistance through DNA repair and autophagy in AR-positive prostate cancer cells. bioRxiv : the preprint server for biology.